From ... in Biology Psychology — Jul 7, 2024

Ginkgo biloba may help to break down microclots caused by the covid spike protein

Ginkgo biloba, also known as the maidenhair tree, is native to China, Japan and Korea, but is also now grown in Europe and the United States. The leaves and seeds from the tree have been used for thousands of years in traditional Chinese medicine and are still used today in supplements and herbal remedies. Modern research primarily focuses on ginkgo extract, which is made from the leaves.

Ginkgo biloba is commonly used to improve memory and cognitive function, as well as to alleviate symptoms of anxiety, glaucoma and dementia. It is believed to improve blood flow to the brain and may help ease circulation problems. Some studies have suggested that it may also help with memory problems caused by dementia or Alzheimer’s disease.

Another possible benefit of ginkgo biloba is the fibrinolytic effects (i.e., prevents blood clots from growing) may ameliorate the microclots and subsequent fibrosis caused by the covid spike protein, which covid “vaccines” induce the body to manufacture after injection.

In the article below, Walter Chestnut refers to “long covid,” but it equally applies to those who are suffering from microclots and fibrosis because of the covid injections.

Let’s not lose touch…Your Government and Big Tech are actively trying to censor the information reported by The Exposé to serve their own needs. Subscribe now to make sure you receive the latest uncensored news in your inbox…

Ginkgo Biloba: A Fibrinolytic and Potential Neurotherapeutic Management of Long Covid

By Walter Chestnut

Given the recent paper discussed yesterday confirming my SPED (Spike Protein Endothelial Disease) hypothesis which includes systemic fibrosis, it is imperative to find therapeutics which can break down the causative microclots. Fortunately, there is a natural therapeutic which has this ability. Yes – once again nature does not disappoint. Today’s hero is ginkgo biloba. It is a most ancient soul.

Ginkgo biloba, commonly known as ginkgo or gingko (/ˈɡɪŋkoʊ, ˈɡɪŋkɡoʊ/ GINK-oh, -⁠goh), also known as the maidenhair tree, is a species of gymnosperm tree native to East Asia. It is the last living species in the order Ginkgoales, which first appeared over 290 million years ago, and fossils very similar to the living species, belonging to the genus Ginkgo, extend back to the Middle Jurassic epoch approximately 170 million years ago. The tree was cultivated early in human history and remains commonly planted, and is widely regarded as a living fossil.
Ginkgo biloba, Wikipedia via EncycloReader

Gingko has a remarkable property (of many) in that it acts as a Plasminogen Activator – it activates the body’s machinery that breaks up clots.

The above graphic shows how the body breaks down clots. This process can be enhanced by exogenous (injected, in this case) plasminogen activators. Two well-known ones are urokinase (“UK”) and streptokinase (“SKA”). Urokinase is found in the kidneys. Streptokinase is a pharmaceutical.

The wonderful thing about gingko is that it achieves the same effect as UK and SKA. It is a plasminogen activator. And, for endothelial cells!

The effects of thrombo-prevention, such as antiplatelet and anticoagulant activity, have been reported with the usage of Ginkgo biloba extract (GbE); however, the detailed mechanism has not yet been fully investigated, especially the role of Krüppel-like factor 2 (KLF2). This study aimed to investigate whether GbE can activate KLF2 and then induce thrombomodulin (TM) and tissue-type plasminogen activator (t-PA) secretion to enhance the effects of thrombo-prevention. Different concentrations of GbE were incubated with human umbilical vein endothelial cells (HUVECs) to evaluate its effect on endothelial cells. We found that KLF2 expression is correlated to the risk of atherosclerosis and venous thromboembolism in clinical practice. In the HUVEC cell model, GbE stimulated the expression of KLF2 in a dose-dependent manner. Moreover, TM and t-PA secretion increased when the cells were cultured with GbE.
Ginkgo biloba Induces Thrombomodulin Expression and Tissue-Type Plasminogen Activator Secretion via the Activation of Krüppel-Like Factor 2 within Endothelial Cells, World Scientific, 2020

I believe this is sufficient evidence to warrant trialling GbE for those suffering from long covid and spike protein injury/pathology (microclotting). There is proof that GbE may have therapeutic benefits for acute covid, particularly in addressing ARDS.

The antiviral effect of EGb is mediated by different mechanisms, including blocking SARS‐CoV‐2 3‐chymotrypsin‐like protease that provides trans‐variant effectiveness. Moreover, EGb impedes the development of pulmonary inflammatory disorders through the diminution of neutrophil elastase activity, the release of proinflammatory cytokines, platelet aggregation, and thrombosis. Thus, EGb can attenuate the acute lung injury and acute respiratory distress syndrome in covid‐19.
Ginkgo biloba in the management of the covid‐19 severity, PubMed, October 2022

Beyond the benefits gingko may have for treating spike protein-induced microclots and subsequent fibrosis, gingko also shows great promise in treating the neurotherapeutic management of long covid.

It is indispensable to continue studying the mechanisms that underlie the pathophysiological process of SARS-CoV-2 infection. This will enable researchers to uncover the therapeutic targets that may be used for their management. According to this review, it may be suggested that Ginkgo biloba has potential positive effects, including anxiolytic, anti-neurotoxic, anti-inflammatory and anti-apoptotic functions, and has been explored in treating neurological disorders, particularly AD, PD, and dementia.
Ginkgo Biloba and Long Covid: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy, MDPI, 22 May 2023

As we have demonstrated, gingko may be a very important therapeutic in managing, perhaps even preventing, the microclots induced by the spike protein of SARS-CoV-2 which leads to a novel form of systemic fibrosis (please see my previous post). Additionally, it may also be beneficial to those suffering from long covid, especially in treating the neurological aspects of the syndrome.

I look forward to enjoying a nice cup or three of ginkgo biloba tea. Please remember, this is a work of medical research and not medical advice. Always consult your primary care provider before using any supplement or medication.

About the Author

Walter Chestnut is an American web developer, market strategist, covid researcher and the principal investigator at WMC Research, a website that contains hypotheses, which are intended to stimulate studies, additional research and dialogue about covid-19. In 2021, he co-authored an opinion piece in France-Soir with the late Luc Montagnier about SARS-CoV-2 accelerating biological age. He also publishes articles on a Substack page titled ‘WMC Research’ which you can subscribe to and follow HERE.

The Expose Urgently Needs Your Help…

Can you please help power The Expose’s honest, reliable, powerful journalism for the years to come…

Your Government & Big Tech organisations
such as Google, Facebook, Twitter & PayPal
are trying to silence & shut down The Expose.

So we need your help to ensure
we can continue to bring you the
facts the mainstream refuse to…

We’re not funded by the Government
to publish lies & propaganda on their
behalf like the mainstream media.

Instead, we rely solely on our support. So
please support us in our efforts to bring you
honest, reliable, investigative journalism
today. It’s secure, quick and easy…